AVANIR PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2014 12 months to Sep 30, 2014	FY2013 12 months to Sep 30, 2013	FY2012 12 months to Sep 30, 2012	FY2011 12 months to Sep 30, 2011
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Allowance for doubtful accounts
Amortization of debt discount and debt issuance costs
Share-based compensation expense
Loss on disposal of assets
Non-cash loss on early extinguishment of debt
Changes in operating assets and liabilities:
Trade receivables, net
Inventories, net
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other liabilities
Accrued compensation and payroll taxes
Deferred product revenues, net
Deferred royalty revenues
Net cash used in operating activities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of restricted investments and restricted cash and cash equivalents
Proceeds from maturities of restricted short-term investments
Proceeds from disposal of fixed asset
Net cash used in investing activities
Cash flows from financing activities:
Repayments of notes payable
Proceeds from debt, net of issuance costs
Proceeds from issuances of common stock, net of commissions and offering costs
Proceeds from exercise of stock options and warrants
Collection of stock subscriptions receivable
Shares surrendered to pay for tax withholding
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year

Supplemental disclosures of cash flow information:
Interest paid
Income taxes paid
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses
Issuance of warrants for common stock in connection with notes payable

Comments